Rubius Therapeutics (NASDAQ:RUBY) and Crispr Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.
Insider and Institutional Ownership
49.8% of Crispr Therapeutics shares are owned by institutional investors. 58.4% of Rubius Therapeutics shares are owned by insiders. Comparatively, 21.4% of Crispr Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This is a breakdown of recent ratings and target prices for Rubius Therapeutics and Crispr Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Rubius Therapeutics currently has a consensus target price of $25.00, suggesting a potential upside of 228.95%. Crispr Therapeutics has a consensus target price of $70.86, suggesting a potential upside of 1.41%. Given Rubius Therapeutics’ higher possible upside, equities analysts plainly believe Rubius Therapeutics is more favorable than Crispr Therapeutics.
Valuation & Earnings
This table compares Rubius Therapeutics and Crispr Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Rubius Therapeutics||N/A||N/A||-$89.19 million||($2.27)||-3.35|
|Crispr Therapeutics||$3.12 million||1,236.34||-$164.98 million||($3.44)||-20.31|
Rubius Therapeutics has higher earnings, but lower revenue than Crispr Therapeutics. Crispr Therapeutics is trading at a lower price-to-earnings ratio than Rubius Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Rubius Therapeutics has a beta of 2.15, suggesting that its share price is 115% more volatile than the S&P 500. Comparatively, Crispr Therapeutics has a beta of 3.3, suggesting that its share price is 230% more volatile than the S&P 500.
This table compares Rubius Therapeutics and Crispr Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Crispr Therapeutics beats Rubius Therapeutics on 7 of the 13 factors compared between the two stocks.
Rubius Therapeutics Company Profile
Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria. It is also developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. In addition, the company is developing RTX-T1D for treating type 1 diabetes; and RTX-PV for treating pemphigus vulgaris. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The company is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, it is developing allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; CTX120, a CAR-T cell product candidate for the treatment of multiple myeloma; CTX130 for the treatment of solid tumors and hematologic malignancies; programs to treat Hurler Syndrome and severe combined immunodeficiency disease, as well as glycogen storage disease Ia; and programs targeting diseases, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreements with Vertex Pharmaceuticals, Incorporated and Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use various therapeutics; and StrideBio LLC to develop adeno-associated viral capsids. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; ViaCyte, Inc. for designing, developing, and commercializing gene-edited allogeneic stem cell therapies for the treatment of diabetes; and ProBioGen AG to develop novel in vivo delivery modalities for CRISPR/Cas9. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.